page contents

«

»

Print this Post

Stocks in Focus: Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR), Yelp Inc (NYSE …

Orlando, FL — (SBWIRE) — 09/03/2013 — Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR), Yelp Inc (NYSE:YELP).

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) shares fell 3.41% to $5.10. The company on August 22 announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal. PRISM was the largest registry ever conducted to further understand prevalence and impact of pseudobulbar affect (PBA) in the United States.

Additionally, the company on August 12 said it reached an exclusive agreement to promote pharmaceutical giant Merck Co.’s type-2 diabetes drug Januvia in long-term care institutional settings in the U.S. Under the accord, Avanir institutional sales force will begin promoting the sitagliptin family of products to health-care practitioners in the long-term care institutional setting in October.

Are investors worried about the recent updates with AVNR? Find out with a free trend analysis HERE

Yelp Inc (NYSE:YELP) stock decreased 3.38% to $51.98. The company announced that management will present at the 2013 Citi Global Technology Conference in New York, NY on Wednesday, September 4, 2013 at 8:15 a.m. ET.

Additionally, the company on August 21 announced the availability of Yelp Brazil. Beginning August 21, people throughout Brazil are able to create accounts on Yelp.com.br to share their opinions about great local businesses. Yelp’s free iPhone and Android applications will be available as well as its free suite of business owner tools: Yelp for Business Owners.

Moreover, the company on July 31 announced financial results for the second quarter ended June 30, 2013. Net loss in the second quarter of 2013 was ($878,000) or $(0.01) per share, compared to a net loss of $(2.0) million, or $(0.03) per share, in the year ago period. Net revenue was $55.0 million in the second quarter of 2013, a 69% growth in net revenue from the second quarter of 2012.

Is YELP going to continue its rally or drop like a rock? Find out with a free trend analysis HERE

About HotStockProfits.Com

Join Our Mobile SMS Alerts By Texting Stocks To 555888

HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure: HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.

(256)

About the author

Mystic Maggie

All of the Mystic Maggie Posts are RSS Reader Feeds from around the web. All copyright remains with the original publisher. No copyright is claimed or intended. Where supplied, links back to the original article are included.

Permanent link to this article: http://yelp-sucks.com/stocks-in-focus-avanir-pharmaceuticals-inc-nasdaqavnr-yelp-inc-nyse.html

//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js

Powered by WordPress Lab
Powered by Yahoo! Answers